Oventus Medical (ASX: OVN) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Oventus Medical Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Oventus Medical (ASX: OVN)
Latest News
Share Market News
Why the Oventus Medical (ASX:OVN) share price is up 7%
OVN ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Oventus Medical
Oventus Medical Ltd. develops oral appliances for the treatment of obstructive sleep disordered and snoring. It offers an oral device under the O2Vent brand. The O2Vent unique design directs the air flow through to the back of the throat, alleviating multiple sites of obstruction including the nose, soft palate and tongue The company was founded by Christopher Patrick Hart in 2012 and is headquartered in Indooroopilly, Australia.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Sue(Susan) MacLeman | Non-Executive DirectorNon-Executive Chairman | Nov 2015 |
Ms MacLeman has more than 30 years of experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector. Sue is also appointed to several academic and government advisory committees including CSIRO Health and Biosecurity Advisory Committee, Prime Ministers Digital Expert Advisory Committee, DMTC Medical Countermeasures and various COVID19 taskforces. She is a member of the Risk Management committee.
|
| Mr Jason (Jake) Nunn | Non-Executive Director | Feb 2020 |
Mr Nunn has more than 25 years of experience in the life science industry as an investor, independent director, research analyst and investment banker. Jason is currently a venture advisor at New Enterprise Associates (NEA), where he was a partner from 2006 to 2018. Jason is a Director of Addex Therapeutics (SIX,Nasdaq: ADXN), Regulus Therapeutics (Nasdaq: RGLS) and Trevena, Inc. (Nasdaq: TRVN). He was a previous Director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc), and a board observer at Vertiflex, Inc. (acquired by Boston Scientific). Prior to NEA, Jason was a Partner specializing in life sciences investing at MPM Capital. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. He is a member of the Risk Management Committee.
|
| Mr Paul Molloy | Non-Executive Director | Dec 2019 |
Mr Molloy has twentyfive years of experience leading a range of public, private and venture capital funded healthcare companies. He is currently President and CEO of ClearFlow Inc., a US-based medical device company. Before joining ClearFlow, Paul was CEO at VasoNova Inc.- a Silicon Valley-based, venture funded vascular navigation company which was acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex' division - ARROW Vascular - having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning. Mr Molloy has also exited a number of leading US medical devices firms, including publicly traded cerebral oxygenation monitoring firm, CAS Medical Inc., and Revolutionary Medical Devices. He also serves on the Board at Augustine Medical a privately held market leader in medical arena temperature management. He is a member of the Risk Management committee.
|
| Mr Stephen (Steve) Denaro | Company Secretary |
-
|
|
| Mr John Cox | Chief Executive Officer | Feb 2022 |
-
|
| John Cox | Chief Executive Officer |
-
|
|
| James Hunter | Chief Financial Officer |
-
|
|
| John Cox | Chief Operating Officer |
-
|
|
| Stephen (Steve) Denaro | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Thorney Investment Group | 48,107,416 | 19.90% |
| Christopher Patrick Hart <Chd Ip Account> | 27,542,517 | 11.39% |
| Bond Street Custodians Limited <Salter D79836 A/C> | 10,000,000 | 4.14% |
| J P Morgan Nominees Australia Pty Limited | 5,525,000 | 2.29% |
| Mr Neil Lawrence Anderson & Ms Genieve Kathryn Anderson <Anderson Family A/C> | 5,348,477 | 2.21% |
| Asia Union Investments Pty Ltd | 4,607,306 | 1.91% |
| Mr Melvyn John Bridges | 4,552,392 | 1.88% |
| Mobius Medical Investments Pty Ltd <Mobius Medical Inv Unit A/C> | 3,752,164 | 1.55% |
| Dixson Trust Pty Ltd | 3,397,739 | 1.41% |
| Mr Anthony John Huntley | 2,750,000 | 1.14% |
| New Highland Pty Ltd <King Family A/C> | 2,171,208 | 0.90% |
| Norfolk Blue Pty Ltd <Norfolk Blue A/C> | 2,000,000 | 0.83% |
| Ceralius Pty Ltd <Bridge A/C> | 1,840,858 | 0.76% |
| Picherit'S Farm Pty Ltd <Huntley Super Fund A/C> | 1,750,000 | 0.72% |
| Spg Trading Pty Ltd | 1,670,765 | 0.69% |
| Mr Michael Frank Manford <Atlo Super Fund A/C> | 1,626,401 | 0.67% |
| Bond Street Custodians Limited <Lam1 D08017 A/C> | 1,604,174 | 0.66% |
| Bond Street Custodians Limited <Rsalte D62375 A/C> | 1,484,105 | 0.61% |
| Pethol (Vic) Pty Ltd <Macdy No 5 Super Fund A/C> | 1,461,379 | 0.60% |
| Wellsey Pty Ltd | 1,413,469 | 0.58% |
